CP
SRPT icon

CenterBook Partners’s Sarepta Therapeutics SRPT Stock Holding History

CenterBook Partners’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-4,397
Closed -$281K – 593
2025
Q1 		$281K Buy
+4,397
New +$463K 0.02% 456
2023
Q3 		– Sell
-6,054
Closed -$693K – 494
2023
Q2 		$693K Buy
+6,054
New +$781K 0.09% 296

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

CenterBook Partners's SRPT Position: Q2 2025 in Review

CenterBook Partners sold out of Sarepta Therapeutics (SRPT) in Q2 2025, closing a stake of 4,397 shares — an estimated $281K sold.

CenterBook Partners first reported a position in SRPT in Q2 2023 and held it in 2 quarters. The position peaked at $693K in Q2 2023. 362 funds tracked by Wall St. Rank hold SRPT as of Q2 2025.

  • CenterBook Partners reported no remaining Sarepta Therapeutics position as of Q2 2025 after selling out during the quarter.
  • CenterBook Partners sold 4,397 Sarepta Therapeutics shares in Q2 2025, an estimated $281K.
  • CenterBook Partners first reported a position in Sarepta Therapeutics in Q2 2023 and held it in 2 quarters.
  • CenterBook Partners's Sarepta Therapeutics position peaked at $693K in Q2 2023.
  • 362 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2025.

Based on CenterBook Partners's 13F filing for Q2 2025, filed 12 Aug 2025.